Drug firm Divi's Laboratories on Monday said its profit after tax (PAT) increased 65 per cent to Rs 589 crore for the ...

In the corresponding quarter of the previous fiscal, Alembic Pharmaceuticals posted a net profit of ₹180.4 crore. The company ...

A significant chunk of revenue for most Indian generic drugmaker comes from the U.S. and fierce competition in the North ...

The stock was last seen trading 5.18 per cent up at Rs 8,415.85. At this price, it has climbed 13.55 per cent in the past one ...

Titan’s revenue from operations in Q3FY25 is estimated to grow 25% YoY, while its net profit is expected to remain flat due ...

Aditya Birla Capital recorded revenue from operations at Rs 9381.35 crore, up 9.28 per cent as against Rs 8584.50 crore ...

Indian drugmaker Alembic Pharmaceuticals reported a lower third-quarter profit on Monday, weighed down by weak local sales of its drugs that treat acute illnesses.

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

MercadoLibre has robust growth with significant ad revenue gains. See why MELI stock's high P/E ratio is justified, and why ...

Audi’s renowned build quality permeates the cabin with a high-class fit and finish. It’s laid out ergonomically, too, with ...

Divi's Labs also said in its exchange filing that it has commenced commercial operations from a part of the Phase 1 of the ...

The company's revenue from operations jumped 25 percent year-on-year to Rs 2,319 crore during the quarter under review.